Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINT: Adaptive Therapy in NSCLC
NCT06524518Phase 2Not yet recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Aug 2024
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Xuanwu Hospital. Primary endpoints: 3-year Disease-Free Survival rate and Median Disease-Free Survival. Planned start Aug 2024; status: not yet recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06524518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06524518.